Scarica l'app Stockscreener
52.41
0.87%
0.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$51.96
Aprire:
$51.35
Volume 24 ore:
2.39M
Relative Volume:
0.61
Capitalizzazione di mercato:
$104.97B
Reddito:
$43.93B
Utile/perdita netta:
$8.53B
Rapporto P/E:
13.71
EPS:
3.824
Flusso di cassa netto:
$5.74B
1 W Prestazione:
+5.84%
1M Prestazione:
+3.21%
6M Prestazione:
-11.95%
1 anno Prestazione:
+30.76%
Intervallo 1D:
$51.35
$52.57
Intervallo di 1 settimana:
$49.88
$52.95
Portata 52W:
$38.63
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Nome
Gsk Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare GSK vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
52.41 | 104.07B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
1,255.40 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
270.24 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
264.96 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
152.55 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
158.86 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2026-01-06 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-11-25 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-06-03 | Downgrade | Berenberg | Buy → Hold |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Downgrade | Jefferies | Buy → Hold |
| 2024-10-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-07-08 | Downgrade | UBS | Buy → Neutral |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-03-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2024-01-03 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-03-17 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Ripresa | Goldman | Buy |
| 2023-01-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Downgrade | UBS | Neutral → Sell |
| 2022-09-15 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Ripresa | Citigroup | Neutral |
| 2022-02-11 | Downgrade | DZ Bank | Buy → Hold |
| 2021-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Hold |
| 2020-11-02 | Aggiornamento | Liberum | Hold → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-02-12 | Downgrade | Shore Capital | Hold → Sell |
| 2020-01-16 | Downgrade | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Iniziato | SVB Leerink | Outperform |
| 2019-11-21 | Aggiornamento | UBS | Neutral → Buy |
| 2019-10-11 | Aggiornamento | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Ripresa | Citigroup | Neutral |
| 2019-09-03 | Aggiornamento | Societe Generale | Sell → Buy |
| 2019-08-13 | Ripresa | JP Morgan | Neutral |
| 2019-06-17 | Ripresa | Morgan Stanley | Underweight |
| 2019-03-08 | Downgrade | Shore Capital | Buy → Hold |
| 2019-02-22 | Downgrade | UBS | Buy → Neutral |
| 2019-01-14 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-08-30 | Downgrade | Liberum | Buy → Hold |
| 2018-04-04 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Aggiornamento | Kepler | Reduce → Hold |
Mostra tutto
Gsk Plc Adr Borsa (GSK) Ultime notizie
Resilient GSK stock steadies after recent earnings beat and sector scrutiny - Ad-hoc-news.de
ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView
GSK Set up for Steady Long-Term Growth As Portfolio and Pipeline Develop - Morningstar
Inside ARMH, STHH and ASMH: Three Semiconductor ADRhedged™ ETFs, and What the Currency Hedge Actually Added - TipRanks
Trump Administration Reportedly Weighs Executive Order on Autism and Vaccines Days After RFK Jr. Hinted At 'Certain Interventions' - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Weekly Recap: £1.9B savings target and Artemis-011 hits Phase III goal - TradingView
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan - TradingView
GSK PLC Sponsored ADR (NYSE:GSK) Announces Quarterly Dividend of $0.45 - MarketBeat
GSK reports $11.28 billion second quarter 2026 revenue - grafa.com
GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals - Sahm
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Revenue Breakdown – BCBA:GSK - TradingView
Bank of New York Mellon Corp Reduces Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK: Glaxosmithkline plcADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - Sahm
Free cash flow of GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs – BCBA:GSK.CI - TradingView
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight - GlobeNewswire Inc.
Dorsey Wright & Associates Takes Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK ends camlipixant programme after CALM-2 miss - grafa.com
Disappointing Data Prompts GSK to Drop Cough Drug Development - Sahm
GSK Stock Quote Price and Forecast - CNN
GSKH ETF Profile: Dividends, Returns (AMEX:GSKH) - TradingView
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer - TradingView
GSK reports Jemperli rectal cancer trial results - grafa.com
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - Sahm
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus - Morningstar
Price to earnings forward of GSK plc Sponsored ADR – MUN:GS70 - TradingView
GSKGSK Plc ADR Latest SEC Filings - Finviz
GS70 Forecast — Price Target — Prediction for 2027 - TradingView
Shareholder in GSK (NYSE: GSK) trims voting stake to 4.96% - Stock Titan
GSK to strengthen oncology pipeline with $10.6B Nuvalent buyout - MSN
Price to earnings forward of GSK plc Sponsored ADR – LS:A3DMHS - TradingView
A3DMHS Forecast — Price Target — Prediction for 2027 - TradingView
GSK plc (GSK) Stock Price, News, Quote & History - Yahoo Finance
GSK (GSK) reports major holder crossing 5% voting rights threshold - Stock Titan
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Actuals & Estimates (BCBA:GSKC) - TradingView
Why GSK's Shingrix is reshaping the shingles vaccine market - AD HOC NEWS
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs - Sahm
Here's Our Take On Theravance Biopharma Inc (NASDAQ:TBPH) and GlaxoSmithKline plc (ADR) (NYSE:GSK)'s Latest Submission - Yahoo Finance
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
GSK secures dual US and EU orphan drug status for momelotinib in VEXAS - grafa.com
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal - Sahm
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent - Sahm
Gsk Plc Adr Azioni (GSK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):